emodin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 5 studies
Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies.
emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs.
Excerpt | Relevance | Reference |
---|---|---|
"New targeted therapy for triple negative breast cancer (TNBC) is an urgent need, as advanced disease responds poorly to conventional chemotherapy." | 1.91 | Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer. ( Agarwal, P; Das, A; Karna, A; Lather, V; Pandita, D; Prajapati, A; Sharma, HK; Uppal, S, 2023) |
"Emodin is an active anthraquinone derivative isolated from Rheum palmatum, with anticancer properties that have been reported to inhibit lung metastasis in a nude mouse xenograft model." | 1.48 | Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes. ( Liu, S; Qin, Y; Song, X; Sun, Z; Wang, Y; Yang, J; Yu, K; Zhang, S; Zhou, X, 2018) |
"Pretreatment with emodin significantly suppressed the TGF-β-induced EMT and cell migration in BT20 cells." | 1.46 | Stromal Fibroblasts from the Interface Zone of Triple Negative Breast Carcinomas Induced Epithelial-Mesenchymal Transition and its Inhibition by Emodin. ( Ho, CT; Hsu, HC; Hung, CM; Lin, YC; Liu, LC; Wang, HY; Way, TD, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 3 (60.00) | 2.80 |
Authors | Studies |
---|---|
Ayoub, AM | 1 |
Amin, MU | 1 |
Ambreen, G | 1 |
Dayyih, AA | 1 |
Abdelsalam, AM | 1 |
Somaida, A | 1 |
Engelhardt, K | 1 |
Wojcik, M | 1 |
Schäfer, J | 1 |
Bakowsky, U | 1 |
Das, A | 1 |
Prajapati, A | 1 |
Karna, A | 1 |
Sharma, HK | 1 |
Uppal, S | 1 |
Lather, V | 1 |
Pandita, D | 1 |
Agarwal, P | 1 |
McDonald, SJ | 1 |
Bullard, BM | 1 |
VanderVeen, BN | 1 |
Cardaci, TD | 1 |
Chatzistamou, I | 1 |
Fan, D | 1 |
Murphy, EA | 1 |
Song, X | 1 |
Zhou, X | 1 |
Qin, Y | 1 |
Yang, J | 1 |
Wang, Y | 1 |
Sun, Z | 1 |
Yu, K | 1 |
Zhang, S | 1 |
Liu, S | 1 |
Hsu, HC | 1 |
Liu, LC | 1 |
Wang, HY | 1 |
Hung, CM | 1 |
Lin, YC | 1 |
Ho, CT | 1 |
Way, TD | 1 |
5 other studies available for emodin and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
Photodynamic and antiangiogenic activities of parietin liposomes in triple negative breast cancer.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Emodin; Humans; Liposomes; Photochemotherapy; Photosensit | 2022 |
Structure-based virtual screening of chemical libraries as potential MELK inhibitors and their therapeutic evaluation against breast cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Early Detection of Cancer; Emodin; Humans; Molecular Docking S | 2023 |
Emodin reduces surgical wounding-accelerated tumor growth and metastasis via macrophage suppression in a murine triple-negative breast cancer model.
Topics: Animals; Cell Line, Tumor; Emodin; Humans; Lung; Lung Neoplasms; Macrophages; Mice; Triple Negative | 2023 |
Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Topics: Adipocytes; Adult; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2018 |
Stromal Fibroblasts from the Interface Zone of Triple Negative Breast Carcinomas Induced Epithelial-Mesenchymal Transition and its Inhibition by Emodin.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Emodin; Epithelial-Mesenchymal Transition; Female; | 2017 |